News & Updates

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

Variables from the Framingham Heart Study Dementia Risk Score (FDRS) are predictive of Alzheimer’s disease (AD) and AD-related dementias (ADRD) in patients with heart failure (HF) or atrial fibrillation (AF), a study has shown.

Women with a history of infertility are more likely to develop reproductive cancers that are related to obesity, as reported in a study.

A real-world study during Hong Kong’s Omicron BA.2.2 wave has shown that viral burden rebound is uncommon in hospitalized COVID-19 patients not requiring supplemental oxygen on admission, regardless of whether they were treated with nirmatrelvir/ritonavir or molnupiravir. However, immunocompromised patients, regardless of oral antiviral use, are more likely to have viral burden rebound.

Mirabegron appears to be as good as vibegron in the treatment of overactive bladder (OAB) in postmenopausal women, with both drugs helping improve symptoms and the parameters of voiding diary, according to a study.

Human papillomavirus (HPV) infection appears to be a risk factor for cardiovascular diseases (CVDs), suggests a recent study. However, women vaccinated against HPV are protected against such risk.

The decision to withdraw life-sustaining therapy (WLST) among acute hospitalized stroke patients is determined by several factors, including age, race, level of consciousness, state region, insurance status, ambulation status at baseline, and stroke centre type, suggests a study presented at ISC 2023.